Functional cross-talk between ras and rho pathways: A ras-specific gtpase-activating protein (p120RasGAP) competitively inhibits the rhogap activity of deleted in liver cancer (DLC) tumor suppressor by masking the catalytic arginine finger

Journal of Biological Chemistry

Volumn 289, Issue 10, 2014, Pages 6839-6849

  Jaiswal, Mamta ^a,d   Dvorsky, Radovan ^a   Amin, Ehsan ^a   Risse, Sarah L ^a   Fansa, Eyad K ^a   Zhang, Si Cai ^a   Taha, Mohamed S ^a   Gauhar, Aziz R ^a   Nakhaei Rad, Saeideh ^a   Kordes, Claus ^a   Koessmeier, Katja T ^a   Cirstea, Ion C ^a,b   Olayioye, Monilola A ^c   Häussinger, Dieter ^a   Ahmadian, Mohammad R ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b FRITZ LIPMANN INSTITUTE   (Germany)

^c UNIVERSITY OF STUTTGART   (Germany)

^d MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CROSSTALK; TUMORS;

GTPASE-ACTIVATING PROTEIN; INTER-RELATIONSHIPS; LIVER CANCERS; MECHANISTIC STUDIES; REGULATORY MECHANISM; STRUCTURE-FUNCTION ANALYSIS; TUMOR SUPPRESSOR PROTEINS; TUMOR SUPPRESSORS;

ARGININE;

ARGININE; DELETED IN LIVER CANCER TUMOR SUPPRESSOR PROTEIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; RAS PROTEIN; RHO FACTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CATALYSIS; COMPETITIVE INHIBITION; CONTROLLED STUDY; DELETED IN LIVER CANCER GENE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE CONTROL; GENE EXPRESSION; GENE INTERACTION; GENE SILENCING; HUMAN; MOLECULAR INTERACTION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MOTIF; PROTEIN STRUCTURE; PROTEIN TARGETING; PXXP MOTIF; REGULATORY MECHANISM; SRC HOMOLOGY DOMAIN; STRUCTURE ACTIVITY RELATION; TUMOR SUPPRESSOR GENE;

ARGININE FINGER; DELETED IN LIVER CANCER; DLC1; GTPASE; KINETICS; MOLECULAR MODELING; P120RASGAP; RHOGAP; SH3 DOMAINS; STRUCTURAL BIOLOGY;

ALANINE; CATALYTIC DOMAIN; DNA MUTATIONAL ANALYSIS; GTPASE-ACTIVATING PROTEINS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; P120 GTPASE ACTIVATING PROTEIN; PROTEIN BINDING; TUMOR SUPPRESSOR PROTEINS;

EID: 84896749766     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.527655     Document Type: Article

References (80)

1. Aznar, S., and Lacal, J. C. (2001) Searching new targets for anticancer drug design: the families of Ras and Rho GTPases and their effectors. Prog. Nucleic Acid Res. Mol. Biol. 67, 193-234
2. Fritz, G., Just, I., and Kaina, B. (1999) Rho GTPases are over-expressed in human tumors. Int. J. Cancer 81, 682-687
3. Pruitt, K., and Der, C. J. (2001) Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett. 171, 1-10
4. Zondag, G. C., Evers, E. E., ten Klooster, J. P., Janssen, L., van der Kammen, R. A., and Collard, J. G. (2000) Oncogenic Ras downregulates Rac activity, which leads to increased Rho activity and epithelial-mesenchymal transition. J. Cell Biol. 149, 775-782
5. Sahai, E., and Marshall, C. J. (2002) RHO-GTPases and cancer. Nat. Rev. Cancer 2, 133-142
6. Khosravi-Far, R., Campbell, S., Rossman, K. L., and Der, C. J. (1998) Increasing complexity of Ras signal transduction: involvement of Rho family proteins. Adv. Cancer Res. 72, 57-107
7. Coleman, M. L., Marshall, C. J., and Olson, M. F. (2004) RAS and RHO GTPases in G1-phase cell-cycle regulation. Nat. Rev. Mol. Cell Biol. 5, 355-366
8. Karnoub, A. E., and Weinberg, R. A. (2008) Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 9, 517-531
9. Asnaghi, L., Vass, W. C., Quadri, R., Day, P. M., Qian, X., Braverman, R., Papageorge, A. G., and Lowy, D. R. (2010) E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPases. Oncogene 29, 2760-2771
10. Shang, X., Moon, S. Y., and Zheng, Y. (2007) p200 RhoGAP promotes cell proliferation by mediating cross-talk between Ras and Rho signaling pathways. J. Biol. Chem. 282, 8801-8811
11. Yang, X. Y., Guan, M., Vigil, D., Der, C. J., Lowy, D. R., and Popescu, N. C. (2009) p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities. Oncogene 28, 1401-1409
12. Scheffzek, K., and Ahmadian, M. R. (2005) GTPase activating proteins: structural and functional insights 18 years after discovery. Cell. Mol. Life Sci. 62, 3014-3038
13. Ligeti, E., Welti, S., and Scheffzek, K. (2012) Inhibition and termination of physiological responses by GTPase activating proteins. Physiol. Rev. 92, 237-272
14. Scheffzek, K., Ahmadian, M. R., and Wittinghofer, A. (1998) GTPaseactivating proteins: helping hands to complement an active site. Trends Biochem. Sci. 23, 257-262
15. Yuan, B. Z., Miller, M. J., Keck, C. L., Zimonjic, D. B., Thorgeirsson, S. S., and Popescu, N. C. (1998) Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res. 58, 2196-2199
16. Durkin, M. E., Yuan, B. Z., Zhou, X., Zimonjic, D. B., Lowy, D. R., Thorgeirsson, S. S., and Popescu, N. C. (2007) DLC-1: a Rho GTPase-activating protein and tumour suppressor. J. Cell. Mol. Med. 11, 1185-1207
17. Liao, Y. C., and Lo, S. H. (2008) Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. Int. J. Biochem. Cell Biol. 40, 843-847
18. Zimonjic, D. B., and Popescu, N. C. (2012) Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics (review). Int. J. Oncol. 41, 393-406
19. Holeiter, G., Heering, J., Erlmann, P., Schmid, S., Jähne, R., and Olayioye, M. A. (2008) Deleted in liver cancer 1 controls cell migration through a Dia1-dependent signaling pathway. Cancer Res. 68, 8743-8751
20. Kim, T. Y., Healy, K. D., Der, C. J., Sciaky, N., Bang, Y. J., and Juliano, R. L. (2008) Effects of structure of Rho GTPase-activating protein DLC-1 on cell morphology and migration. J. Biol. Chem. 283, 32762-32770
21. Kim, T. Y., Vigil, D., Der, C. J., and Juliano, R. L. (2009) Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility. Cancer Metastasis Rev. 28, 77-83
22. Scholz, R. P., Regner, J., Theil, A., Erlmann, P., Holeiter, G., Jähne, R., Schmid, S., Hausser, A., and Olayioye, M. A. (2009) DLC1 interacts with 14-3-3 proteins to inhibit RhoGAP activity and block nucleocytoplasmic shuttling. J. Cell Sci. 122, 92-102
23. Lukasik, D., Wilczek, E., Wasiutynski, A., and Gornicka, B. (2011) Deleted in liver cancer protein family in human malignancies (review). Oncol. Lett. 2, 763-768
24. Yam, J. W., Ko, F. C., Chan, C. Y., Jin, D. Y., and Ng, I. O. (2006) Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res. 66, 8367-8372
25. Liao, Y. C., Si, L., deVere White, R. W., and Lo, S. H. (2007) The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. J. Cell Biol. 176, 43-49
26. Qian, X., Li, G., Asmussen, H. K., Asnaghi, L., Vass, W. C., Braverman, R., Yamada, K. M., Popescu, N. C., Papageorge, A. G., and Lowy, D. R. (2007) Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proc. Natl. Acad. Sci. U.S.A. 104, 9012-9017
27. Chan, L. K., Ko, F. C., Ng, I. O., and Yam, J. W. (2009) Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function. PLoS One 4, e5572
28. Tripathi, V., Popescu, N. C., and Zimonjic, D. B. (2013) DLC1 induces expression of E-cadherin in prostate cancer cells through Rho pathway and suppresses invasion. Oncogene 4, 1-10
29. Li, G., Du, X., Vass, W. C., Papageorge, A. G., Lowy, D. R., and Qian, X. (2011) Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK). Proc. Natl. Acad. Sci. U.S.A. 108, 17129-17134
30. Erlmann, P., Schmid, S., Horenkamp, F. A., Geyer, M., Pomorski, T. G., and Olayioye, M. A. (2009) DLC1 activation requires lipid interaction through a polybasic region preceding the RhoGAP domain. Mol. Biol. Cell 20, 4400-4411
31. Fauchereau, F., Herbrand, U., Chafey, P., Eberth, A., Koulakoff, A., Vinet, M. C., Ahmadian, M. R., Chelly, J., and Billuart, P. (2003) The RhoGAP activity of OPHN1, a new F-actin-binding protein, is negatively controlled by its amino-terminal domain. Mol. Cell. Neurosci. 23, 574-586
32. Eberth, A., and Ahmadian, M. R. (2009) In vitro GEF and GAP assays. Curr. Protoc. Cell Biol. Chapter 14, Unit 14.19
33. Colón-González, F., Leskow, F. C., and Kazanietz, M. G. (2008) Identification of an autoinhibitory mechanism that restricts C1 domain-mediated activation of the Rac-GAP2-chimaerin. J. Biol. Chem. 283, 35247-35257
34. Jian, X., Brown, P., Schuck, P., Gruschus, J. M., Balbo, A., Hinshaw, J. E., and Randazzo, P. A. (2009) Autoinhibition of Arf GTPase-activating protein activity by the BAR domain in ASAP1. J. Biol. Chem. 284, 1652-1663
35. Zhou, Y. T., Chew, L. L., Lin, S. C., and Low, B. C. (2010) The BNIP-2 and Cdc42GAP homology (BCH) domain of p50RhoGAP/Cdc42GAP sequesters RhoA from inactivation by the adjacent GTPase-activating protein domain. Mol. Biol. Cell 21, 3232-3246
36. Moskwa, P., Paclet, M. H., Dagher, M. C., and Ligeti, E. (2005) Autoinhibition of p50 Rho GTPase-activating protein (GAP) is released by prenylated small GTPases. J. Biol. Chem. 280, 6716-6720
37. Pamonsinlapatham, P., Hadj-Slimane, R., Lepelletier, Y., Allain, B., Toccafondi, M., Garbay, C., and Raynaud, F. (2009) p120-Ras GTPase activating protein (RasGAP): a multi-interacting protein in downstream signaling. Biochimie 91, 320-328
38. Ahmadian, M. R., Hoffmann, U., Goody, R. S., and Wittinghofer, A. (1997) Individual rate constants for the interaction of Ras proteins with GTPaseactivating proteins determined by fluorescence spectroscopy. Biochemistry 36, 4535-4541
39. Ahmadian, M. R., Stege, P., Scheffzek, K., and Wittinghofer, A. (1997) Confirmation of the arginine-finger hypothesis for the GAP-stimulated GTP-hydrolysis reaction of Ras. Nat. Struct. Biol. 4, 686-689
40. Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., and Wittinghofer, A. (1997) The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 277, 333-338
41. Leblanc, V., Tocque, B., and Delumeau, I. (1998) Ras-GAP controls Rhomediated cytoskeletal reorganization through its SH3 domain. Mol. Cell. Biol. 18, 5567-5578
42. Chan, P. C., and Chen, H. C. (2012) p120RasGAP-mediated activation of c-Src is critical for oncogenic Ras to induce tumor invasion. Cancer Res. 72, 2405-2415
43. Clark, G. J., and Der, C. J. (1995) Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res. Treat. 35, 133-144
44. Clark, G. J., Westwick, J. K., and Der, C. J. (1997) p120 GAP modulates Ras activation of Jun kinases and transformation. J. Biol. Chem. 272, 1677-1681
45. Herbrand, U., and Ahmadian, M. R. (2006) p190-RhoGAP as an integral component of the Tiam1/Rac1-induced downregulation of Rho. Biol. Chem. 387, 311-317
46. Wang, Z., Tung, P. S., and Moran, M. F. (1996) Association of p120 ras GAP with endocytic components and colocalization with epidermal growth factor (EGF) receptor in response to EGF stimulation. Cell Growth Differ. 7, 123-133
47. Hu, K. Q., and Settleman, J. (1997) Tandem SH2 binding sites mediate the RasGAP-RhoGAP interaction: a conformational mechanism for SH3 domain regulation. EMBO J. 16, 473-483
48. Risse, S. L., Vaz, B., Burton, M. F., Aspenström, P., Piekorz, R. P., Brunsveld, L., and Ahmadian, M. R. (2013) SH3-mediated targeting of Wrch1/RhoU by multiple adaptor proteins. Biol. Chem. 394, 421-432
49. Jaiswal, M., Dubey, B. N., Koessmeier, K. T., Gremer, L., and Ahmadian, M. R. (2012) Biochemical assays to characterize Rho GTPases. Methods Mol. Biol. 827, 37-58
50. Eberth, A., Lundmark, R., Gremer, L., Dvorsky, R., Koessmeier, K. T., McMahon, H. T., and Ahmadian, M. R. (2009) A BAR domain-mediated autoinhibitory mechanism for RhoGAPs of the GRAF family. Biochem. J. 417, 371-377
51. Wu, X., Knudsen, B., Feller, S. M., Zheng, J., Sali, A., Cowburn, D., Hanafusa, H., and Kuriyan, J. (1995) Structural basis for the specific interaction of lysine-containing proline-rich peptides with the N-terminal SH3 domain of c-Crk. Structure 3, 215-226
52. Eberth, A., Dvorsky, R., Becker, C. F., Beste, A., Goody, R. S., and Ahmadian, M. R. (2005) Monitoring the real-time kinetics of the hydrolysis reaction of guanine nucleotide-binding proteins. Biol. Chem. 386, 1105-1114
53. Ross, B., Kristensen, O., Favre, D., Walicki, J., Kastrup, J. S., Widmann, C., and Gajhede, M. (2007) High resolution crystal structures of the p120 RasGAP SH3 domain. Biochem. Biophys. Res. Commun. 353, 463-468
54. Schneidman-Duhovny, D., Inbar, Y., Nussinov, R., and Wolfson, H. J. (2005) PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res. 33, W363-W367
55. Brooks, B. R., Brooks, C. L., 3rd, Mackerell, A. D., Jr., Nilsson, L., Petrella, R. J., Roux, B., Won, Y., Archontis, G., Bartels, C., Boresch, S., Caflisch, A., Caves, L., Cui, Q., Dinner, A. R., Feig, M., Fischer, S., Gao, J., Hodoscek, M., Im, W., Kuczera, K., Lazaridis, T., Ma, J., Ovchinnikov, V., Paci, E., Pastor, R. W., Post, C. B., Pu, J. Z., Schaefer, M., Tidor, B., Venable, R. M., Woodcock, H. L., Wu, X., Yang, W., York, D. M., and Karplus, M. (2009) CHARMM: the biomolecular simulation program. J. Comput. Chem. 30, 1545-1614
56. Scouras, A. D., and Daggett, V. (2011) The Dynameomics rotamer library: amino acid side chain conformations and dynamics from comprehensive molecular dynamics simulations in water. Protein Sci. 20, 341-352
57. Eccleston, J. F., Moore, K. J., Morgan, L., Skinner, R. H., and Lowe, P. N. (1993) Kinetics of interaction between normal and proline 12 Ras and the GTPase-activating proteins, p120-GAP and neurofibromin. The significance of the intrinsic GTPase rate in determining the transforming ability of ras. J. Biol. Chem. 268, 27012-27019
58. Morrison, J. F. (1969) Kinetics of the reversible inhibition of enzymecatalysed reactions by tight-binding inhibitors. Biochim. Biophys. Acta 185, 269-286
59. Kärkkäinen, S., Hiipakka, M., Wang, J. H., Kleino, I., Vähä-Jaakkola, M., Renkema, G. H., Liss, M., Wagner, R., and Saksela, K. (2006) Identification of preferred protein interactions by phage-display of the human Src homology-3 proteome. EMBO Rep. 7, 186-191
60. Rittinger, K., Walker, P. A., Eccleston, J. F., Smerdon, S. J., and Gamblin, S. J. (1997) Structure at 1.65 A of RhoA and its GTPase-activating protein in complex with a transition-state analogue. Nature 389, 758-762
61. Dvorsky, R., and Ahmadian, M. R. (2004) Always look on the bright site of Rho: structural implications for a conserved intermolecular interface. EMBO Rep. 5, 1130-1136
62. Moon, S. Y., and Zheng, Y. (2003) Rho GTPase-activating proteins in cell regulation. Trends Cell Biol. 13, 13-22
63. Tcherkezian, J., and Lamarche-Vane, N. (2007) Current knowledge of the large RhoGAP family of proteins. Biol. Cell 99, 67-86
64. Rossman, K. L., Der, C. J., and Sondek, J. (2005) GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat. Rev. Mol. Cell Biol. 6, 167-180
65. Aittaleb, M., Boguth, C. A., and Tesmer, J. J. (2010) Structure and function of heterotrimeric G protein-regulated Rho guanine nucleotide exchange factors. Mol. Pharmacol. 77, 111-125
66. DiNitto, J. P., Lee, M. T., Malaby, A. W., and Lambright, D. G. (2010) Specificity and membrane partitioning of Grsp1 signaling complexes with Grp1 family Arf exchange factors. Biochemistry 49, 6083-6092
67. Gureasko, J., Kuchment, O., Makino, D. L., Sondermann, H., Bar-Sagi, D., and Kuriyan, J. (2010) Role of the histone domain in the autoinhibition and activation of the Ras activator Son of Sevenless. Proc. Natl. Acad. Sci. U.S.A. 107, 3430-3435
68. Jaiswal, M., Gremer, L., Dvorsky, R., Haeusler, L. C., Cirstea, I. C., Uhlenbrock, K., and Ahmadian, M. R. (2011) Mechanistic insights into specificity, activity, and regulatory elements of the regulator of G-protein signaling (RGS)-containing Rho-specific guanine nucleotide exchange factors (GEFs) p115, PDZ-RhoGEF (PRG), and leukemia-associated RhoGEF (LARG). J. Biol. Chem. 286, 18202-18212
69. Mitin, N., Betts, L., Yohe, M. E., Der, C. J., Sondek, J., and Rossman, K. L. (2007) Release of autoinhibition of ASEF by APC leads to CDC42 activation and tumor suppression. Nat. Struct. Mol. Biol. 14, 814-823
70. Scholz, R. P., Gustafsson, J. O., Hoffmann, P., Jaiswal, M., Ahmadian, M. R., Eisler, S. A., Erlmann, P., Schmid, S., Hausser, A., and Olayioye, M. A. (2011) The tumor suppressor protein DLC1 is regulated by PKD-mediated GAP domain phosphorylation. Exp. Cell Res. 317, 496-503
71. Ching, Y. P., Wong, C. M., Chan, S. F., Leung, T. H., Ng, D. C., Jin, D. Y., and Ng, I. O. (2003) Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J. Biol. Chem. 278, 10824-10830
72. Wong, C. M., Lee, J. M., Ching, Y. P., Jin, D. Y., and Ng, I. O. (2003) Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res. 63, 7646-7651
73. Healy, K. D., Hodgson, L., Kim, T. Y., Shutes, A., Maddileti, S., Juliano, R. L., Hahn, K. M., Harden, T. K., Bang, Y. J., and Der, C. J. (2008) DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAPdependent and independent mechanisms. Mol. Carcinog. 47, 326-337
74. Chan, F. K., Chung, S. S., Ng, I. O., and Chung, S. K. (2012) The RhoA GTPase-activating protein DLC2 modulates RhoA activity and hyperalgesia to noxious thermal and inflammatory stimuli. Neurosignals 20, 112-126
75. Leung, T. H., Ching, Y. P., Yam, J. W., Wong, C. M., Yau, T. O., Jin, D. Y., and Ng, I. O. (2005) Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc. Natl. Acad. Sci. U.S.A. 102, 15207-15212
76. Kawai, K., Kiyota, M., Seike, J., Deki, Y., and Yagisawa, H. (2007) STARTGAP3/ DLC3 is a GAP for RhoA and Cdc42 and is localized in focal adhesions regulating cell morphology. Biochem. Biophys. Res. Commun. 364, 783-789
77. Roof, R. W., Haskell, M. D., Dukes, B. D., Sherman, N., Kinter, M., and Parsons, S. J. (1998) Phosphotyrosine (p-Tyr)-dependent and-independent mechanisms of p190 RhoGAP-p120 RasGAP interaction: Tyr 1105 of p190, a substrate for c-Src, is the sole p-Tyr mediator of complex formation. Mol. Cell. Biol. 18, 7052-7063
78. Gigoux, V., L'Hoste, S., Raynaud, F., Camonis, J., and Garbay, C. (2002) Identification of Aurora kinases as RasGAP Src homology 3 domain-binding proteins. J. Biol. Chem. 277, 23742-23746
79. Yang, Y. S., Garbay, C., Duchesne, M., Cornille, F., Jullian, N., Fromage, N., Tocque, B., and Roques, B. P. (1994) Solution structure of GAP SH3 domain by 1H NMR and spatial arrangement of essential Ras signaling-involved sequence. EMBO J. 13, 1270-1279
80. Harkiolaki, M., Lewitzky, M., Gilbert, R. J., Jones, E. Y., Bourette, R. P., Mouchiroud, G., Sondermann, H., Moarefi, I., and Feller, S. M. (2003) Structural basis for SH3 domain-mediated high-affinity binding between Mona/Gads and SLP-76. EMBO J. 22, 2571-2582